CN116761895A - 使用了可溶型clec2的癌症患者的血栓症风险的预测方法 - Google Patents

使用了可溶型clec2的癌症患者的血栓症风险的预测方法 Download PDF

Info

Publication number
CN116761895A
CN116761895A CN202280009906.2A CN202280009906A CN116761895A CN 116761895 A CN116761895 A CN 116761895A CN 202280009906 A CN202280009906 A CN 202280009906A CN 116761895 A CN116761895 A CN 116761895A
Authority
CN
China
Prior art keywords
cancer
thrombosis
concentration
patient
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280009906.2A
Other languages
English (en)
Chinese (zh)
Inventor
藤井幸彦
川村雅英
白川嘉门
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pu Heji
Original Assignee
LSI Medience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LSI Medience Corp filed Critical LSI Medience Corp
Publication of CN116761895A publication Critical patent/CN116761895A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN202280009906.2A 2021-01-13 2022-01-13 使用了可溶型clec2的癌症患者的血栓症风险的预测方法 Pending CN116761895A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021-003671 2021-01-13
JP2021003671 2021-01-13
PCT/JP2022/000891 WO2022154045A1 (ja) 2021-01-13 2022-01-13 可溶型ｃｌｅｃ２を用いた癌患者における血栓症リスクの予測方法

Publications (1)

Publication Number Publication Date
CN116761895A true CN116761895A (zh) 2023-09-15

Family

ID=82448474

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280009906.2A Pending CN116761895A (zh) 2021-01-13 2022-01-13 使用了可溶型clec2的癌症患者的血栓症风险的预测方法

Country Status (6)

Country Link
US (1) US20240288435A1 (https=)
EP (1) EP4279606A4 (https=)
JP (1) JP7808059B2 (https=)
KR (1) KR20230131222A (https=)
CN (1) CN116761895A (https=)
WO (1) WO2022154045A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090297508A1 (en) * 2005-04-25 2009-12-03 University Of Yamanashi Compositions and methods for treating hemostasis disorders associated with clec-2 signal transduction
CA2610910A1 (en) 2005-06-09 2006-12-21 Paul H. Mcpherson Methods and compositions for the diagnosis of venous thromboembolic disease
CN104093741B (zh) * 2011-03-22 2016-12-07 公益财团法人癌研究会 小鼠抗Aggrus单克隆抗体
JP6078845B2 (ja) * 2012-09-28 2017-02-15 株式会社Ｌｓｉメディエンス 可溶型ｃｌｅｃ−２に基づく血小板活性化測定方法
CA2993624A1 (en) * 2015-08-07 2017-02-16 Thomas Helledays Stiftelse For Medicinsk Forskning Method for diagnosisng cancer or cancer-associated thrombosis by measuring levels of h3cit in plasma
FR3048001B1 (fr) 2016-02-18 2018-02-09 Diagnostica Stago Methode de dosage des d-dimeres specifiques de la maladie thromboembolique veineuse
EP4113524A4 (en) * 2020-02-28 2024-03-06 LSI Medience Corporation METHOD FOR MEASURING PLATELE ACTIVATION BASED ON SOLUBLE CLEC-2 AND PLATELE COUNT

Also Published As

Publication number Publication date
US20240288435A1 (en) 2024-08-29
EP4279606A1 (en) 2023-11-22
EP4279606A4 (en) 2024-12-18
KR20230131222A (ko) 2023-09-12
WO2022154045A1 (ja) 2022-07-21
JP7808059B2 (ja) 2026-01-28
JPWO2022154045A1 (https=) 2022-07-21

Similar Documents

Publication Publication Date Title
Tian et al. The diagnostic value of serum C-reactive protein, procalcitonin, interleukin-6 and lactate dehydrogenase in patients with severe acute pancreatitis
Bates D-dimer assays in diagnosis and management of thrombotic and bleeding disorders
CN115190973B (zh) 基于可溶性clec-2与血小板数的血小板活化测定方法
Unno et al. Superficial thrombophlebitis of the lower limbs in patients with varicose veins
CN119199150A (zh) 作为对象的细胞外容量状态的标志物的MR-proADM
CN105765382A (zh) 用于预测具有心血管疾病或心血管事件的风险的方法和试剂盒
Karpińska et al. A prothrombotic state and denser clot formation in patients following acute limb ischemia of unknown cause
Ver Elst et al. Plasma D-dimer concentrations in different clinical conditions
Chae et al. The correlation of serum osteoprotegerin with non-traditional cardiovascular risk factors and arterial stiffness in patients with pre-dialysis chronic kidney disease: results from the KNOW-CKD Study
JP2004503254A (ja) リポタンパク質と急性期タンパク質との複合体を検出し、系の不全または致死のリスクの増加を予測する方法
CN116761895A (zh) 使用了可溶型clec2的癌症患者的血栓症风险的预测方法
EP4350350A1 (en) Method for assessing risk of hemorrhagic stroke using soluble clec2
EP4636404A2 (en) Method for evaluating risk of acute cerebral vascular disease using soluble clec2
Hunt et al. Venous thromboembolism and thrombophilia testing
RU2664448C2 (ru) Способ прогнозирования развития тромбоэмболии легочной артерии у онкологических больных с флеботромбозом нижних конечностей
HK40085757A (en) Method for measuring platelet activation based on soluble clec-2 and platelet count
Otero et al. Biomarkers of Venous Thromboembolism Recurrence after Discontinuation of Low Molecular Weight Heparin Treatment for Cancer-Associated Thrombosis (HISPALIS-Study). Cancers 2022, 14, 2771
Reddy et al. Clinical Surgery Journal
HK40106384A (en) Method for assessing risk of hemorrhagic stroke using soluble clec2
Ateş et al. The Association Between Mean Neutrophil Volume and Dipping Status in Newly Diagnosed Hypertensive Patients
Wang et al. Predictive value of combined CRP/ALB ratio and DD/FIB ratio for MODS in patients with severe polytrauma.
CA3006390C (en) Mr-proadm as marker for the extracellular volume status of a subject
HK40115553A (zh) 作为对象的细胞外容量状态的标志物的mr-proadm
Wang et al. Prognostic Factors of Complications After Thoracoscopic Lobectomy for Non-Small Cell Lung Cancer-A Retrospective Study
Lippi et al. Laboratory diagnostics in septic disseminated intravascular coagulation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20240522

Address after: Ehime Prefecture, Japan

Applicant after: Pu Heji

Country or region after: Japan

Address before: Tokyo, Japan

Applicant before: LSI MEDIENCE Corp.

Country or region before: Japan